Kyverna Therapeutics' miv-cel CAR-T therapy successfully treated Stiff Person Syndrome in a Phase 2 trial: 81%! Swipe to see →
On April 21, 2026, at the American Academy of Neurology annual meeting, researchers from Kyverna Therapeutics presented data that fundame...
Stiff Person Syndrome is one of the rarest and most misunderstood diseases in neurology. Affecting approximately 1 in 1 million people gl...
Before 2026, treatment for SPS relied on a handful of approaches, none of which addressed the underlying cause:
CAR-T (Chimeric Antigen Receptor T-cell) therapy represents a fundamentally different approach. Instead of suppressing the immune system ...
The KYSA-8 Phase 2 clinical trial enrolled 26 patients with moderate-to-severe SPS who had failed or were inadequately controlled on exis...
The KYSA-8 results matter for several reasons that extend beyond SPS itself:
Visit our portal and read the full story!